Thiogenesis hires Brisco Capital for investor relations
Thiogenesis Therapeutics said it has engaged Brisco Capital for investor relations. The company is a clinical-stage biotech developing sulfur-based therapeutics for rare diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.